PHOENIX, Feb. 06, 2018 (GLOBE NEWSWIRE) -- GB Sciences, Inc. (OTCQB:GBLX) (the “company”), discusses 2017 achievements and 2018 operations expectations, on Stock Day Podcast with Everett Jolly.
“It is great to have GB Sciences Inc. back on the show,” said Jolly. “The stock has done tremendously in recent months and monthly revenues are increasing.”
GB Sciences Inc., is a science oriented cannabis company working with top scientist in the industry to develop evidence based compounds to treat specific diseases. The company’s growth strategy, based on three areas of focus, has allowed GB Science to develop recurring revenue streams, grow geographically, and make progress scientifically.
John Poss commented, “We are thrilled to be making strides to help patients who suffer from multiple diseases. We are using our work in biotech and genetics to propagate specific strains of cannabis that we believe will target conditions like Parkinson’s and heart disease.”
The company currently holds multiple provisional patents and will embark on patient trials in the year to come.
To view the interview in its entirety, click here: https://upticknewswire.com/featured-interview-ceo-john-poss-of-gb-sciences-inc-otcqb-gblx-3
About GB Sciences, Inc.
GB Sciences, Inc. (GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company’s goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company’s research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.
Contact
GB Sciences, Inc.,
1-866-721-0297, or http://gbsciences.com
Tom Arcuragi, Sr VP, tom@gbsciences.com
About Uptick Newswire and the “Stock Day Podcast”
Uptick Newswire is a private company reaching out to the masses keeping investors and shareholders up to date on company news and bringing transparency to the undervalued, undersold, micro-cap stocks of the market and is the sole producer of the Uptick Network “Stock Day” Podcast. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire and has recently launched the Video Interview Studio located in Phoenix, Arizona with its new host Kathryn Donnelly.
Follow us and keep an eye on Uptick’s YouTube, Twitter, and Facebook for additional radio and video shows produced by Uptick! https://www.youtube.com/watch?v=kU5SVLp4org
Investors Hangout is a proud sponsor of Stock Day and Uptick Newswire encourages listeners to visit GB Sciences’s message board on: https://investorshangout.com/GB-Sciences-Inc-GBLX-67373/